Erratum

2023 ESH Guidelines for the management of

arterial hypertension The Task Force for the
Downloaded from http://journals.lww.com/jhypertension by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0

management of arterial hypertension of the

hCywCX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 01/24/2024

European Society of Hypertension: Endorsed by the

International Society of Hypertension (ISH) and the
European Renal Association (ERA): Erratum
In ESH 2023 Guidelines [1], the color in columns 3, 4 and 5 of the row for Class of Recommendation I in Figure 2
has been corrected from white to dark blue in the online version of the paper to match the color used in all
other Tables referring to the Level of Evidence. The color of the text has been changed from black to white to
aid reading. The corrected Figure 2 is shown below. Additionally, in section 7.5 on page 1916, ‘... to minimize
the problem of postexercise hypotension [411–413].’ should be changed to ‘... due to the immediate BP
lowering effects of exercise [411–413].’

Class of Recommendation Level of Evidence

Definition Definition Interpretation
Evidence or general agreement A - RCT or meta-analysis of Strong evidence. Evidence
that a treatment/test/procedure is RCTs with CVD of high certainty. Unlikely
beneficial, useful or effective AND outcomes that future studies will
that potential benefits clearly - Single trial enough if change the effect estimate
outweigh potential risk sufficient power and substantially
without important
limitations a

Conflicting evidence or opinion B - RCT with surrogate Moderate evidence.

about the benefit, usefulness and measures (BP, HMOD)
effectiveness of a - Observational studies
treatment/test/procedure OR with CVD outcomes and
uncertainty about benefit-risk no major limitationsa
balance - Meta-analyses including
the above study types
Evidence with some
uncertainty. Future studies
may modify, at least the
magnitude of, the effect
estimate

Evidence or general agreement C - Observational studies of Weak evidence. Evidence

that a treatment/test/procedure is surrogate measures of low certainty. Future
not beneficial, useful or effective - Any study type may be studies may change the
OR that potential risks outweigh downgraded to level C effect estimate
the potential benefit due to limitationsa substantially.
- Expert opinion (EO)

REFERENCE
1. Mancia G, Kreutz R, Brunstr€om M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial
hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the
International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023; 41:1874–2071.

194 www.jhypertension.com Volume 42  Number 1  January 2024

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.